ResMed (RMD)
(Delayed Data from NYSE)
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
Boston Scientific Stock Gains From Market Expansion, Innovation
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
by Zacks Equity Research
Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
by Zacks Equity Research
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
MMSI's Stock Declines Despite Q3 Earnings Beat, Higher Gross Margin
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the third quarter.
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket
by Zacks Equity Research
TECH registers continued momentum across its Diagnostics & Spatial Biology segment.
DaVita Stock Declines After Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
DVA's robust Dialysis patient service revenues drives its third-quarter performance.
5 Low-Leverage Stocks to Buy Ahead of Big Tech Earnings Releases
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy RMD, CCB, KEX, APOG and LMB.
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock
by Zacks Equity Research
Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.
ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock
by Zacks Equity Research
Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.
Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down
by Zacks Equity Research
Despite AVTR's continued stability in the Education and Advanced Technology end markets, it reports an overall soft third-quarter performance.
PHG vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PHG vs. RMD: Which Stock Is the Better Value Option?
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TFX Stock to Gain From Launch of New Vascular Access Devices in Canada
by Zacks Equity Research
Teleflex launches the next-generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada.
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
Zacks.com featured highlights Leidos, NetApp, ResMed, Trane Technologies and Travelers
by Zacks Equity Research
Leidos, NetApp, ResMed, Trane Technologies and Travelers have been highlighted in this Screen of The Week article.
ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 8.37% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Top Dividend Stocks That Promise Substantial Growth
by Sweta Killa
Leidos Holdings, NetApp, ResMed, Trane Technologies and Travelers could be compelling picks for investors looking for dividend stocks.
Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Is ResMed Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
RMD's robust mask business and efforts to boost its SaaS business are encouraging.
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PHG or RMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PHG vs. RMD: Which Stock Is the Better Value Option?